Genotyping and macrolide-resistant mutation of Bordetella pertussis in East and South-East Asia.

23S rRNA Bordetella pertussis East and Southeast Asia Macrolide-resistant A2047G mutation Multilocus variable-number tandem-repeat analysis Whole-genome sequencing

Journal

Journal of global antimicrobial resistance
ISSN: 2213-7173
Titre abrégé: J Glob Antimicrob Resist
Pays: Netherlands
ID NLM: 101622459

Informations de publication

Date de publication:
12 2022
Historique:
received: 02 09 2022
revised: 05 10 2022
accepted: 10 10 2022
pubmed: 22 10 2022
medline: 21 12 2022
entrez: 21 10 2022
Statut: ppublish

Résumé

Macrolide-resistant Bordetella pertussis (MRBP) has been emerging and prevailing in mainland China since 2011. In this study, we aimed to investigate the genotype and macrolide resistance of circulating B. pertussis in East and Southeast Asia using genetic analyses. A total of 302 DNA extracts from clinical specimens and isolates from 2010 to 2020 were analyzed: 145 from Vietnam, 76 from Cambodia, 48 from Taiwan, and 33 from Japan. Genotypes were determined by multilocus variable-number tandem-repeat analysis (MLVA). Macrolide-resistant A2047G mutation in B. pertussis 23S rRNA was investigated using the duplex Cycleave real-time polymerase chain reaction (PCR) assay. Whole-genome sequencing was performed on two MRBP isolates that were identified for the first time in Taiwan. Overall, 286 DNA extracts (95%) generated a complete MLVA genotype and 283 DNA extracts (94%) yielded a complete result for the A2047G mutation analysis. The A2047G mutation was detected in 18 DNA extracts: fourteen from Vietnam, one from Cambodia, two from Taiwan, and one from Japan. Most of them (78%) showed the genotypes MT104 and MT195, which have previously been reported in Chinese MRBP isolates. Further, the Taiwanese MRBP isolates were classified into the MT104 clade of Chinese MRBP isolates. After MRBP emerged and spread in mainland China, it may have spread to East and Southeast Asia in the 2010s. Continued surveillance targeting the A2047G mutation of MRBP is needed to prevent further spread of this emerging pathogen.

Identifiants

pubmed: 36270447
pii: S2213-7165(22)00238-7
doi: 10.1016/j.jgar.2022.10.007
pmc: PMC9750937
pii:
doi:

Substances chimiques

Macrolides 0
Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

263-269

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Références

Lancet Reg Health West Pac. 2021 Feb 05;8:100098
pubmed: 34327426
Pediatrics. 2015 Feb;135(2):331-43
pubmed: 25560446
Emerg Infect Dis. 2019 Dec;25(12):2205-2214
pubmed: 31742507
Int J Infect Dis. 2015 Jun;35:24-6
pubmed: 25861926
Antimicrob Agents Chemother. 2013 Oct;57(10):5193-4
pubmed: 23877687
PLoS One. 2015 Sep 25;10(9):e0138941
pubmed: 26406905
BMC Pharmacol Toxicol. 2014 Feb 20;15:6
pubmed: 24555709
PLoS One. 2012;7(2):e31985
pubmed: 22348138
J Int Med Res. 2022 Feb;50(2):3000605221078782
pubmed: 35225710
Pediatr Infect Dis J. 2018 Jun;37(6):e145-e148
pubmed: 29088029
Eur J Clin Microbiol Infect Dis. 2016 Jul;35(7):1211-4
pubmed: 27146879
Expert Rev Vaccines. 2020 Nov;19(11):1093-1099
pubmed: 33034224
Pediatr Infect Dis J. 2021 Feb 1;40(2):87-90
pubmed: 33021592
Clin Microbiol Infect. 2014 Nov;20(11):O825-30
pubmed: 24816168
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
J Med Microbiol. 2012 Dec;61(Pt 12):1662-1668
pubmed: 22918864
Pediatr Infect Dis J. 2019 Apr;38(4):370-376
pubmed: 30882726
Emerg Infect Dis. 2017 Apr;23(4):699-701
pubmed: 28322702
Front Microbiol. 2022 Jul 18;13:901617
pubmed: 35923401
J Med Microbiol. 2008 Dec;57(Pt 12):1577-1580
pubmed: 19018032
J Clin Microbiol. 2015 Nov;53(11):3418-22
pubmed: 26224847
Emerg Microbes Infect. 2019;8(1):461-470
pubmed: 30898080
Pediatr Infect Dis J. 2005 May;24(5 Suppl):S58-61
pubmed: 15876927
Int J Infect Dis. 2017 Sep;62:56-58
pubmed: 28751008
PLoS One. 2014 Aug 11;9(8):e104984
pubmed: 25110940
Emerg Infect Dis. 2020 Oct;26(10):2511-2513
pubmed: 32946738
Clin Microbiol Infect. 2013 Jun;19(6):E260-2
pubmed: 23480481
Jpn J Infect Dis. 2020 Sep 24;73(5):361-362
pubmed: 32350216

Auteurs

Kentaro Koide (K)

Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.

ShuMan Yao (S)

Centre for Diagnostics and Vaccine Development, Centres for Disease Control, Taipei, Taiwan.

Chuen-Sheue Chiang (CS)

Centre for Diagnostics and Vaccine Development, Centres for Disease Control, Taipei, Taiwan.

Phung Thi Bich Thuy (PTB)

Department of Molecular Biology for Infectious Disease, Vietnam National Children's Hospital, Hanoi, Vietnam.

Do Thi Thuy Nga (DTT)

Division of General Internal Medicine, Centre for Tropical Diseases, Vietnam National Children's Hospital, Hanoi, Vietnam.

Do Thu Huong (DT)

Division of General Internal Medicine, Centre for Tropical Diseases, Vietnam National Children's Hospital, Hanoi, Vietnam.

Tran Minh Dien (TM)

Surgical Intensive Care Unit, Vietnam National Children's Hospital, Hanoi, Vietnam.

Ork Vichit (O)

National Immunization Program, Ministry of Health, Cambodia.

Yong Vutthikol (Y)

National Immunization Program, Ministry of Health, Cambodia.

Siphan Sovannara (S)

National Immunization Program, Ministry of Health, Cambodia.

Chham Samnang (C)

Vaccine-Preventable Diseases and Immunization, World Health Organization, Cambodia.

Ikuyo Takayama (I)

Research Centre for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo, Japan.

Akira Ainai (A)

Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.

Noriko Nakajima (N)

Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.

Nao Otsuka (N)

Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.

Kazunari Kamachi (K)

Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan. Electronic address: kamachi@nih.go.jp.

Akihiko Saitoh (A)

Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH